-
Lanicemine (AZD6765) is a low-trapping NMDA
receptor antagonist that was
under development by
AstraZeneca for the
management of
severe and treatment-resistant...
- non-heteroaromatic aryl
groups (i.e., both
rings are carbocyclic). An
exception is
lanicemine,
which features a
heteroaromatic pyridyl ring.
Additional heteroaromatic...
- However,
multiple other NMDA
receptor antagonists,
including memantine,
lanicemine, rislenemdaz, rapastinel, and 4-chlorokynurenine, have thus far failed...
-
Fluorolintane Gacyclidine Ibogaine Ibogamine Indantadol Ketamine Ketobemidone Lanicemine Levomethadone Levomethorphan Levomilnacipran Levorphanol Loperamide Memantine...
-
Fluorolintane Gacyclidine Ibogaine Ibogamine Indantadol Ketamine Ketobemidone Lanicemine Levomethadone Levomethorphan Levomilnacipran Levorphanol Loperamide Memantine...
-
dizocilpine site
antagonist Kynurenic acid –
endogenous glycine site
antagonist Lanicemine – low-trapping
dizocilpine site
antagonist LY-235959 –
glutamate site...
-
Fluorolintane Gacyclidine Ibogaine Ibogamine Indantadol Ketamine Ketobemidone Lanicemine Levomethadone Levomethorphan Levomilnacipran Levorphanol Loperamide Memantine...
-
antagonists in
clinical trials for
depression included lanicemine, esketamine, and rapastinel, with
lanicemine being the most advanced. By 2013, AV-101 had successfully...
-
Fluorolintane Gacyclidine Ibogaine Ibogamine Indantadol Ketamine Ketobemidone Lanicemine Levomethadone Levomethorphan Levomilnacipran Levorphanol Loperamide Memantine...
-
Fluorolintane Gacyclidine Ibogaine Ibogamine Indantadol Ketamine Ketobemidone Lanicemine Levomethadone Levomethorphan Levomilnacipran Levorphanol Loperamide Memantine...
